Patient Organization Reporting
Pfizer partners with many medical, scientific, patient and civic organizations to support their programs and activities, such as health education and scientific research. This support takes many forms, including grants, charitable contributions and partnerships for efforts that strengthen communities, and work toward a healthier world. Working with these organizations allows Pfizer to better understand the needs of the patients who take our medicines, while helping these medical, scientific and patient organizations inform and address the needs of those they serve.
Pfizer is committed to the principle of transparency — the disclosure of activities reflecting participation in efforts of public interest. These include such areas as funding for educational activities, the status of Pfizer's pharmaceutical post-marketing commitments, Pfizer's pipeline of experimental medicines, the registration and reporting of results of clinical trials and political contributions in the U.S.
The information reported here includes grants to support independent medical education, support for fellowship, scholarship and visiting professorship programs, grants to patient organizations, medical and scientific associations, and academic or other medical centers, charitable contributions, healthcare-related support to civic organizations and healthcare-related non-promotional sponsorships to organizations. To learn more about these funding types click here.
EFPIA Patient Organization Reporting
Patient organizations aim to improve the lives of people with a particular disease or medical condition. Working with patient organizations allows us to support their activities, where appropriate, and to better understand patients’ unmet needs and how those needs can best be met. By obtaining patient insights, we gain a better knowledge of the burden of disease, which informs our efforts to develop medicines and support programs for the patient community.
In providing funding for or working with patient organizations, Pfizer’s guiding principles are independence and transparency. Relationships with patient organizations are both valuable and essential, and by ensuring these organizations maintain their independence and that our relationships are transparent, we can be confident and proud of the relationships we have developed. Sharing information about these relationships in a straightforward and open way will, we hope, help explain the critical value these relationships bring to patient management.
We believe that transparency is essential to building and maintaining confidence in Pfizer and in our medicines and strongly support the work being done by The European Federation of Pharmaceutical Industries and Associations (EFPIA) to improve transparency across the pharmaceutical industry.
- Pfizer Support to European and International Patient Organisations in 2025
- Pfizer Support to European and International Patient Organisations in 2024
Austria (PDF)
Belarus (No transfer of value to patient organisations in 2024)
Belgium
Bosnia and Herzegovina (PDF)
Bulgaria (PDF)
Croatia (PDF)
Cyprus (PDF)
Czech Republic (PDF)
Denmark (PDF)
Estonia (PDF)
Finland (PDF)
France
Germany (PDF)
Greece (PDF)
Hungary (PDF)
Iceland (No transfer of value to patient organisations in 2024)
Ireland (PDF)
Italy (PDF)
Latvia (PDF)
Lithuania (PDF)
Luxembourg (No transfer of value to patient organisations in 2024)
Malta (PDF)
Netherlands (PDF)
North Macedonia (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland (PDF)
Turkey (PDF)
Ukraine (PDF)
United Kingdom (PDF)
- Pfizer Support to European and International Patient Organisations in 2023
Austria (PDF)
Belarus (No transfer of value to patient organisations in 2023)
Bosnia and Herzegovina (PDF)
Bulgaria (PDF)
Belgium
Croatia (PDF)
Cyprus (PDF)
Czech Republic (PDF)
Denmark (PDF)
Estonia (PDF)
France (PDF)
Finland (PDF)
Germany (PDF)
Greece (PDF)
Hungary (PDF)
Iceland (No transfer of value to patient organisations in 2023)
Ireland (PDF)
Italy (PDF)
Latvia (No transfer of value to patient organisations in 2023)
Lithuania (PDF)
Luxembourg (No transfer of value to patient organisations in 2023)
Malta (No transfer of value to patient organisations in 2023)
Netherlands (PDF)
North Macedonia (PDF)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland (PDF)
Turkey (PDF)
Ukraine (PDF)
United Kingdom (PDF) - Pfizer Support to European and International Patient Organisations in 2022
Austria (PDF)
Belarus (No transfer of value to patient organisations in 2022)
Belgium
Bosnia and Herzegovina (PDF) (PDF - Local Template)
Bulgaria (PDF)
Croatia (PDF)
Cyprus (PDF)
Czechia (PDF)
Denmark (PDF)
Estonia (PDF)
Finland (PDF)
France (Donations and expenses PDF) (Partnerships and benefits PDF)
Germany (PDF)
Greece (PDF)
Hungary (PDF)
Iceland (No transfer of value to patient organisations in 2022)
Ireland (PDF)
Italy (PDF)
Latvia (No transfer of value to patient organisations in 2022)
Lithuania (PDF)
Luxembourg (No transfer of value to patient organisations in 2022)
Malta (PDF)
Netherlands (PDF)
North Macedonia (No transfer of value to patient organisations in 2022)
Norway (PDF)
Poland (PDF)
Portugal (PDF)
Romania (PDF)
Russia (PDF)
Serbia (PDF)
Slovakia (PDF)
Slovenia (PDF)
Spain (PDF)
Sweden
Switzerland (PDF)
Turkey (PDF)
Ukraine (PDF)
United Kingdom (PDF)
Transparency in Grants
In 2008, Pfizer began reporting grants and charitable contributions provided to medical, scientific and patient organizations in the US. This reflects our commitment to increasing transparency around the support Pfizer provides to organizations that work to improve the health of patients and advance science. This support is one way we contribute to the improvement of patients' lives and the advancement of scientific research, in conjunction with our core business of developing innovative medicines.
To that end, Pfizer's support of these organizations and activities is reported on Pfizer.com. This reporting is a condition of accepting such grants and charitable contributions. Details disclosed include the recipient organization's name, a brief description of the program for which the grant or charitable contribution was given, and the amount of the funding.
View the 2024 US Medical, Scientific and Patient Organizations Grants Report Details- Funding Type
Charitable Contributions – Donations to 501(c)(3) not-for-profit organizations, used to support patient education and advocacy, improvements in patient care or general operating support, among other things.
Fellowships – Support provided to US medical schools, teaching hospitals and other institutions intended to aid junior faculty and talented researchers early in their careers.
Independent Grants for Learning & Change (IGL&C) – Medical education grants from the office of IGL&C in support of healthcare quality improvement initiatives and independent education for healthcare professionals (HCPs), including but not limited to, continuing medical education (CME).
Non-Medical Education Grants – Funding to medical, scientific and patient organizations for a variety of non-medical education purposes, such as general operating support and support of meetings.
Scholarships – Funding to augment specialty training and encourage development of senior faculty scientists, similar to fellowships.
Visiting Professorships – Funding that enables schools and teaching hospitals to recruit an expert of their choice to lead a 3-day information exchange on pre-determined topics with students, faculty, nurses and others.
Funding Requests for Healthcare Activities – Funding in support of a wide array of initiatives and charitable causes including patient advocacy and education.
Collaborations – Funding a healthcare related activity or project in which Pfizer and one or more Organizations work as equal partners on the design, development and implementation of the project with the purpose of advancing specified shared objectives. In addition to funding and partnering on the project, Pfizer also receives the right to use the output/materials created.
Sponsorships – Funding opportunities provided to organizations that are healthcare-related and non-promotional in nature.
- Recipient Type
Academic Medical Centers – Accredited medical schools or academic hospitals in which a majority of the physicians are faculty members; may include other health professional schools, such as public health, nursing, or graduate schools in the life sciences.
Other Medical Centers – A single entity or loose conglomerate not directly affiliated with a medical school or university, usually focused on patient care and residency training.
Medical Associations – Professional membership organizations for physicians.
Professional Associations – Professional membership organizations for health care professionals such as nurses, nurse practitioners, physician assistants and pharmacists.
Patient Organizations – Non-profit organizations that represent the interests of patients by providing information and services, support for increased medical research, and/or access to health care.
Scientific Associations – Organizations that exist to promote an academic or scientific discipline through activities including regular meetings or conferences for the presentation and discussion of new research results, and publishing or sponsoring academic journals.
Civic Organizations – Non-profit organizations that promote social welfare.
- Why is Pfizer disclosing financial support for these organizations and activities?
Pfizer is proud of its longstanding support for organizations that share its commitment to improving public health. Pfizer also discloses information on its pipeline of experimental medicines, clinical trials, post marketing commitments, political contributions and payments to US health care professionals. We are actively looking for more ways to better communicate with the public about how we operate, consistent with our statement on transparency in grants.
- What details is Pfizer disclosing about payments to Health Care Professionals?
The following information is disclosed:
Payments to:
- All practicing HCPs (defined as Health Care Professionals who can prescribe medicines)
- Major institutions for ongoing clinical trials
- All principal investigators and other entities for Phase I-IV clinical trials beginning after July 1, 2009
Payments for:
- Development, research and commercial consulting
- Promotional speaking
- Phase I-IV clinical trials
- Investigator-initiated research
- Meals, reimbursable travel expenses, educational materials and other non-educational items allowed by local market guidelines and Pfizer policy
- What is a Medical Education grant and where can I find more information about requesting one?
Pfizer supports the efforts of independent organizations in their mission to improve patient care through quality improvement initiatives as well as continuing education for healthcare professionals. Pfizer also supports health care charitable contributions. For more information about the grant types Pfizer supports and how to apply, visit our grants page.
For information on the broad range of programs Pfizer supports, visit www.pfizer.com/responsibility .
- Is the volume of funding activities consistent throughout the calendar year?
No. Funding of grants and charitable contributions may fluctuate throughout the year, following the pattern of requests for such funding from medical, scientific and patient organizations.
- How does Pfizer ensure that grants and charitable contributions do not pose a conflict of interest with recipient organizations?
Pfizer respects the integrity of the medical, scientific and patient organizations with whom we partner. As such, we strive to achieve the highest level of ethical business conduct in our partnership grants and charitable contributions. Funding support to US-based medical, scientific and patient organizations is in no way intended to influence or reward the recipient for present, past, or future use or support of Pfizer medicines, or to gain access for promotion purposes, or to influence the outcome of a clinical trial. In addition, none of these payments is given to reward recipient organizations for influencing or attempting to influence specific legislation, regulation or governmental health care policies, nor are these payments given on behalf of government officials or elected officials. This support is one way we contribute to the improvement of patients' lives and the advancement of scientific research, in conjunction with our core business of developing innovative medicines.
- How do I get more information about transactions awarded to my organization?
Please visit our contact us page here.